Endoscopic submucosal dissection

Fujifilm Showcases New Endoscopy Innovations for the Detection, Diagnosis, and Treatment of Diseases at Digestive Disease Week 2022

Retrieved on: 
Tuesday, May 17, 2022
Physician, Mammography, EUS, Knowledge, Degenerative disease, DDW, ESD, Surgeon, Adenoma, Endoscopy, Magnetic resonance imaging, Enterprise imaging, Colonoscopy, Solution, Image, Comparison, Society, OEM, DOI, FDA, Gastroenterology, Endoscopic submucosal dissection, Technology, ASGE, Fujifilm, Gastrointestinal tract, Exhibition, Diagnosis, Laboratory, ASC, GLOBE, Pharmaceutical industry, Medical imaging, Cassette tape

Fujifilm will showcase its entire portfolio of endoscopic imaging solutions for core gastrointestinal (GI), therapeutic, interventional, and third space endoscopy in booth 4343.

Key Points: 
  • Fujifilm will showcase its entire portfolio of endoscopic imaging solutions for core gastrointestinal (GI), therapeutic, interventional, and third space endoscopy in booth 4343.
  • New to DDW this year, Fujifilm will demonstrate:
    ELUXEO VISION is Fujifilms new image enhancement technology developed to improve visualization during GI, colorectal, and advanced endoscopy and surgical procedures.
  • The new image enhancement technology enables real-time visualization of hemoglobin oxygen saturation (StO2) levels in tissue using laparoscopic and/or endoscopic imaging.
  • Being able to detect StO2 levels helps surgeons identify potentially ischemic tissue, better positioning them to prevent tissue necrosis.

Micro-Tech Endoscopy Announces the Release of its New Submucosal Lifting Agent

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Digestive system, Clinical medicine, Medicine, Membrane biology, Submucosa, Gastrointestinal cancer, Gastrointestinal tract, ESD, Endoscopic submucosal dissection

ANN ARBOR, Mich., June 22, 2021 /PRNewswire/ -- Micro-Tech Endoscopy recently expanded its EMR and ESD portfolio with the launch of its BlueBoost submucosal lift.

Key Points: 
  • ANN ARBOR, Mich., June 22, 2021 /PRNewswire/ -- Micro-Tech Endoscopy recently expanded its EMR and ESD portfolio with the launch of its BlueBoost submucosal lift.
  • BlueBoost is a viscous submucosal injection fluid designed to increase the efficiency of resection procedures.
  • Lifts and separates the gastrointestinal mucosa from the submucosal layer to help identify the margin around the lesion.
  • Micro-Tech Endoscopy has operations in America, Asia, and Europe and leverages this global reach to refine the products the company provides to partners.

EndoClot Plus, Inc. Announces FDA Clearance of GI Submucosal Lifting Product

Retrieved on: 
Wednesday, February 19, 2020
FDA, Surgery, Medical devices, Health, Oncology, Medical specialties, Medicine, Branches of biology, Digestive system, Diagnostic gastroenterology, Membrane biology, Submucosa, Polyp, Endoscopy, Gastrointestinal tract, Adenoma, Endoscopic submucosal dissection

(EPI), a privately held medical device company announced the FDA 510(k) clearance of EndoClot Submucosal Injection Agent (EndoClot SIA) manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China.

Key Points: 
  • (EPI), a privately held medical device company announced the FDA 510(k) clearance of EndoClot Submucosal Injection Agent (EndoClot SIA) manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China.
  • EndoClot SIA is the first starch-derived submucosal injection system cleared in the U.S. market for endoscopic removal of polyps, adenomas, early stage cancers and other gastrointestinal mucosal lesions.
  • EndoClot Plus is focused on utilizing its polymer expertise to develop customized medical devices to meet GI clinical needs.
  • With its innovative technology platforms EndoClot Plus aims to become the leading company in creating new biomaterial therapeutic solutions for GI Endoscopy.

Global Minimally Invasive Surgery (MIS) Market Study 2019 - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2016-2026) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 26, 2019
Surgery, Health, Medicine, Clinical medicine, Endoscopy, Minimally-invasive surgery, Digestive system surgery, Laparoscopy, Surgery, Endoscopic mucosal resection, Robot-assisted surgery, Minimally invasive procedure, Endoscopic submucosal dissection

Rise in demand for precise and technically advanced devices contributes to the growth of the endoscopic mucosal resection segment in minimally invasive surgery (MIS) market.

Key Points: 
  • Rise in demand for precise and technically advanced devices contributes to the growth of the endoscopic mucosal resection segment in minimally invasive surgery (MIS) market.
  • Therefore, rise in need and demand for advanced products that increase therapeutic outcome drives the global minimally invasive surgery (MIS) market.
  • In terms of procedure, the minimally invasive surgery (MIS) market has been classified into laparoscopic surgery, robotic surgery, endoscopic mucosal resection, and endoscopic sub-mucosal dissection.
  • The minimally invasive surgery (MIS) market report concludes with the company profiles section that includes information about the major players in the market.

Lumendi Brands Exclusive Tissue Manipulation Feature for Company’s DiLumen EIP

Retrieved on: 
Tuesday, June 11, 2019
Surgery, Health, Biotechnology, Hospitals, Medical devices, General Health, Medicine, Medical specialties, Clinical medicine, Digestive system, Membrane biology, Submucosa, Polyp, Endoscopy, Endoscopic submucosal dissection

View the full release here: https://www.businesswire.com/news/home/20190611005268/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190611005268/en/
    The DiLumen +DR is a new feature of the fore balloon assembly to help facilitate tissue manipulation for easier dissection and resection of polyps without the need for surgical intervention.
  • TheDiLumen +DR consistently provideseffective tissue retraction, continuous tissue tension, and superior visualization of submucosal tissue planes enabling precise dissection.
  • According to Dr. Peter Johann, CEO of Lumendi, Ltd., This modification to DiLumen has the potential to revolutionize tissue manipulation during both ESD and EMR.
  • Lumendi Ltd. holds a worldwide exclusive license from Cornell University on the DiLumen technology.